Sugi Predict

Sugi Predict / Compounds / SCHEMBL92829

SCHEMBL92829

SCHEMBL92829

NC(=O)CCC(N)C(=O)NP

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BLM P54132 2/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ PMP22 Q01453 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ DPP4 P27487 3/20 0.53
▸ DPP8 Q6V1X1 3/20 0.53
▸ DPP9 Q86TI2 3/20 0.53
▸ GRM8 O00222 1/20 0.37
▸ GRM6 O15303 1/20 0.37
▸ GRIN2D O15399 1/20 0.37
▸ GRIN3B O60391 1/20 0.37
▸ GSR P00390 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ GRIK1 P39086 1/20 0.37
▸ GRM5 P41594 1/20 0.37
▸ GRIA1 P42261 1/20 0.37
▸ GRIA2 P42262 1/20 0.37
▸ GRIA3 P42263 1/20 0.37
▸ SLC1A3 P43003 1/20 0.37
▸ SLC1A2 P43004 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92848 0.89 KMT2A (0.43) BLMALOX15PMP22KMT2ADPP4
SCHEMBL9021158 0.83 GRM8 (0.58) BLMALOX15PMP22KMT2ADPP4
SCHEMBL8773315 0.82 BLM (0.60) BLMALOX15PMP22KMT2ADPP4
SCHEMBL11478144 0.80 BLM (0.58) BLMALOX15PMP22KMT2ADPP4
SCHEMBL29833669 0.80 BLM (0.58) BLMALOX15PMP22KMT2ADPP4
SCHEMBL21447963 0.80 BLM (0.58) BLMALOX15PMP22KMT2ADPP4
SCHEMBL4321248 0.80 BLM (0.58) BLMALOX15PMP22KMT2ADPP4
SCHEMBL288407 0.80 BLM (0.58) BLMALOX15PMP22KMT2ADPP4
SCHEMBL24864555 0.78 BLM (0.56) BLMALOX15PMP22KMT2ADPP4
SCHEMBL5325523 0.78 DPP4 (0.58) BLMALOX15PMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2012-11-08 — — US disclosed
US-8283517-B2 Transgenic mouse models of Aβ overexpression PROBIODRUG AG (DE) 2012-10-09 — — US disclosed
US-20120237475-A1 Novel Inhibitors PROBIODRUG AG (DE) 2012-09-20 — — US disclosed
US-20120183974-A1 NOVEL GENES RELATED TO GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-07-19 — — US disclosed
US-8129160-B2 Method of screening for inhibitors of glutaminyl cyclase activity PROBIODRUG AG (DE) 2012-03-06 — — US disclosed
US-20110262388-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-10-27 — — US disclosed
US-20110212853-A1 NOVEL DIAGNOSTIC METHOD PROBIODRUG AG (DE) 2011-09-01 — — US disclosed
US-7732162-B2 Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases PROBIODRUG AG (DE) 2010-06-08 — — US disclosed
US-20100125086-A1 USE OF ISOQC INHIBITORS PROBIODRUG AG (DE) 2010-05-20 — — US disclosed
US-20100119475-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-05-13 — — US disclosed
US-20100009337-A1 NOVEL GENES RELATED TO GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-01-14 — — US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 — — US disclosed
US-20090149394-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES PROBIODRUG AG (DE) 2009-06-11 — — US disclosed
US-20090098052-A1 TRANSGENIC MICE PROBIODRUG AG (DE) 2009-04-16 — — US disclosed
US-20080286810-A1 Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; drug screening PROBIODRUG AG (DE) 2008-11-20 — — US disclosed
US-20080286231-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-11-20 — — US disclosed
US-20080262063-A1 Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: PROBIODRUG AG (DE) 2008-10-23 — — US disclosed
US-20080249083-A1 NOVEL GENES RELATED TO GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-10-09 — — US disclosed
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-09-11 — — US disclosed
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119475-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, GLUL BLM 3746/4885ALOX15 2750/4885PMP22 1754/4885
US-20110262388-A1 NOVEL INHIBITORS GLUL, QPCT, GLS BLM 2724/4885ALOX15 1370/4885PMP22 1334/4885
US-20090149394-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES GLS, GLUL, GLS2 BLM 1709/4885ALOX15 461/4885PMP22 2954/4885
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL BLM 4123/4885ALOX15 1014/4885PMP22 1874/4885
US-20090098052-A1 TRANSGENIC MICE APP, PSEN1, PSEN2 BLM 4259/4885ALOX15 2817/4885PMP22 299/4885
US-20080286231-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, QPCT BLM 3614/4885ALOX15 2505/4885PMP22 3860/4885
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL BLM 3930/4885ALOX15 1090/4885PMP22 3197/4885
US-20080249083-A1 NOVEL GENES RELATED TO GLUTAMINYL CYCLASE QPCT, QPCTL, GLUL BLM 3511/4885ALOX15 3194/4885PMP22 3191/4885
US-20120237475-A1 Novel Inhibitors GLS, NQO2, GLS2 BLM 2464/4885ALOX15 3221/4885PMP22 4015/4885
US-20100125086-A1 USE OF ISOQC INHIBITORS QPCT, QPCTL, GGCT BLM 2404/4885ALOX15 1931/4885PMP22 35/4885
US-20080262063-A1 Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: MAPT, SLC10A1, REN BLM 3351/4885ALOX15 1737/4885PMP22 3886/4885
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL BLM 3823/4885ALOX15 1027/4885PMP22 1613/4885
US-20120283259-A1 NOVEL INHIBITORS GLUL, QPCT, GLS BLM 2724/4885ALOX15 1370/4885PMP22 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.